ZURICH, Sept 8 (Reuters) – Sandoz aims to more than double net sales from 2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, where it outlined its new Bio100 biosimilars strategy, pivoting its focus from generics to biosimilars.
“Our Bio100 ambitions are set to position biosimilars to become the majority of our sales,” Sandoz’s Chief Executive Richard Saynor said in a statement.
Sandoz said it is also targeting annual net sales growth at a mid-to-high single-digit rate at constant currencies from 2025 to 2030, banking on its biosimilars portfolio, which it wants to increase to 100 drugs by 2040, from 13 today.
At its previous capital markets day in 2023, ahead of its spin-off from former parent Novartis, the company had aimed for mid-single digit sales growth by 2028, a goal it says remains unchanged.
(Reporting by Marleen KaesebierEditing by Dave Graham)
